Xvivo Perfusion Q3: Below expectations
Research Note
2017-10-27
09:29
Sales in Q3 came in lower than our forecast, affected by a negative currency effect. Operating costs were lower than expected, resulting in an EBIT that was in line with expectations. The company provided an update on the ongoing clinical trials, which are progressing according to plan. Our fair value remains unchanged at SEK 105 per share.
AN
Arvid Necander
Disclosures and disclaimers